Gu X, et al. - In this retrospective study, researchers tested the effectiveness of repeated injections of intravitreal ranibizumab with or without photodynamic therapy (PDT) for the treatment of polypoidal choroidal vasculopathy (PCV) and determined the possible factors predictive of visual outcomes. They reviewed the outcomes of the initial treatment of 40 PCV patients with 3 monthly injections of ranibizumab (Lucentis, 0.5 mg). In the short term, 3 monthly injections of ranibizumab as an initial treatment could significantly improve VA in PCV patients. Ranibizumab treatment could stabilize VA in most PCV patients at 12 months postinjection. Predictive factors for the relative improvement of VA at the final follow-up were the baseline VA, the reduction in subretinal fluids and the greatest lesion diameter. Patients receiving extra therapy with PDT had a considerably higher rate of polyp regression.